Pulmatrix Cash Halves Amid Merger Uncertainty, Revenue Dries Up

TL;DR

**PULM is a zombie company; if the Cullgen merger fails, it's lights out, and even if it succeeds, existing shareholders get scraps.**

AI Summary

Pulmatrix, Inc. (PULM) reported a significant decline in financial performance for the nine months ended September 30, 2025, with revenues dropping to $0 from $7.803 million in the prior year. The company's net loss widened to $4.234 million, compared to a net loss of $7.573 million for the same period in 2024, primarily due to a substantial reduction in operating expenses from $15.614 million to $4.261 million. Research and development expenses decreased dramatically from $7.160 million to $41 thousand, and general and administrative expenses fell from $5.836 million to $4.220 million. Cash and cash equivalents plummeted by 49.65% from $9.521 million at December 31, 2024, to $4.794 million at September 30, 2025. The company's total assets decreased by 49.9% from $9.943 million to $4.982 million over the same period. A critical strategic development is the proposed merger with Cullgen Inc., where pre-Merger Cullgen stockholders are expected to own approximately 96.4% of the combined company, and Pulmatrix stockholders approximately 3.6%. The merger, approved by Pulmatrix stockholders on June 16, 2025, is contingent on Nasdaq listing approval and China Security Regulatory Commission (CSRC) approval, which has not yet been received as of the filing date.

Why It Matters

This filing reveals Pulmatrix is in a precarious financial state, with cash reserves nearly halved and no revenue, making the Cullgen merger a make-or-break event. For investors, the 3.6% ownership stake in the combined entity signals significant dilution and a near-complete pivot from Pulmatrix's original biopharmaceutical focus. Employees face uncertainty as the company's future is entirely dependent on the merger's success and potential asset sales. Customers of Pulmatrix's iSPERSE technology or clinical assets will see their future tied to the combined company's strategic direction or the outcome of an asset sale. The broader market will watch this as a case study in biotech M&A, particularly regarding regulatory hurdles with the CSRC, which could set precedents for other cross-border deals.

Risk Assessment

Risk Level: high — The company's future operations are 'highly dependent on the success of the Merger,' and there are 'no assurances that the Merger will be successfully consummated.' Cash and cash equivalents decreased by 49.65% from $9.521 million to $4.794 million, and total assets decreased by 49.9% from $9.943 million to $4.982 million, indicating a rapidly deteriorating financial position without the merger. The company also reported $0 in revenue for the nine months ended September 30, 2025, compared to $7.803 million in the prior year.

Analyst Insight

Investors should consider divesting PULM shares due to the high risk of merger failure, significant shareholder dilution (3.6% ownership post-merger), and the company's dire financial state with no revenue. If the merger is not consummated, the board may pursue dissolution and liquidation, offering little to no value to current shareholders.

Financial Highlights

debt To Equity

0.05

revenue

$0

operating Margin

N/A

total Assets

$4.982M

total Debt

$0.249M

net Income

$(4.234)M

eps

$(1.16)

gross Margin

N/A

cash Position

$4.794M

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $4.794M — Cash and Cash Equivalents (Decreased by 49.65% from $9.521M at Dec 31, 2024)
• $0 — Revenue (For the nine months ended September 30, 2025, down from $7.803M in 2024)
• $(4.234)M — Net Loss (For the nine months ended September 30, 2025, compared to $(7.573)M in 2024)
• 3.6% — Pulmatrix Shareholder Ownership (Expected ownership in combined company post-merger)
• $41K — Research and Development Expenses (For the nine months ended September 30, 2025, a significant drop from $7.160M in 2024)
• $4.982M — Total Assets (Decreased by 49.9% from $9.943M at Dec 31, 2024)
• $420K — Termination Fee (Pulmatrix to Cullgen) (Potential fee if merger terminates under specific circumstances)
• $2.8M — Termination Fee (Cullgen to Pulmatrix) (Potential fee if merger terminates under specific circumstances)
• 3,652,285 — Common Shares Outstanding (As of October 13, 2025, unchanged from December 31, 2024)

Key Players & Entities

• Pulmatrix, Inc. (company) — Registrant and biopharmaceutical company
• Cullgen Inc. (company) — Merger partner
• Nasdaq Stock Market LLC (regulator) — Exchange where PULM is listed and requires approval for merger
• China Security Regulatory Commission (regulator) — Regulatory body whose approval is pending for the merger
• $4.794 million (dollar_amount) — Cash and cash equivalents as of September 30, 2025
• $9.521 million (dollar_amount) — Cash and cash equivalents as of December 31, 2024
• $4.234 million (dollar_amount) — Net loss for the nine months ended September 30, 2025
• $7.803 million (dollar_amount) — Revenue for the nine months ended September 30, 2024
• 3.6% (dollar_amount) — Expected ownership of pre-Merger Pulmatrix stockholders in the combined company
• 96.4% (dollar_amount) — Expected ownership of pre-Merger Cullgen stockholders in the combined company

FAQ

Risk Factors

• Deteriorating Financial Position [high — financial]: The company's cash and cash equivalents have plummeted by 49.65% to $4.794 million as of September 30, 2025, from $9.521 million at the end of 2024. Total assets have also decreased by 49.9% to $4.982 million. This severe cash burn and asset reduction raise concerns about the company's ability to fund ongoing operations and future development.
• Merger Contingencies and Approvals [high — regulatory]: The proposed merger with Cullgen Inc. is contingent on Nasdaq listing approval and China Security Regulatory Commission (CSRC) approval, neither of which has been received as of the filing date. Delays or failure to obtain these approvals could jeopardize the merger and the company's strategic direction.
• Drastic Reduction in R&D Spending [high — operational]: Research and development expenses have been slashed from $7.160 million for the nine months ended September 30, 2024, to just $41 thousand for the same period in 2025. This dramatic cut suggests a significant scaling back or halt in product development activities, potentially impacting future growth prospects.
• Significant Net Loss [medium — financial]: The company reported a net loss of $4.234 million for the nine months ended September 30, 2025, compared to a net loss of $7.573 million in the prior year. While the net loss has narrowed, it is primarily due to a substantial reduction in operating expenses rather than revenue generation.
• Merger Termination Fees [medium — legal]: The merger agreement includes termination fees, with Pulmatrix potentially owing Cullgen $420,000 and Cullgen potentially owing Pulmatrix $2.8 million under specific circumstances. These fees represent financial exposure and potential costs if the merger does not proceed as planned.
• Minimal Revenue Generation [high — financial]: For the nine months ended September 30, 2025, Pulmatrix reported zero revenue, a stark contrast to the $7.803 million generated in the same period of 2024. This complete absence of revenue raises serious questions about the company's current business model and ability to generate income.

Industry Context

Pulmatrix operates in the biopharmaceutical sector, focusing on inhaled therapeutics for respiratory diseases. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often pursue mergers or acquisitions to gain access to new technologies, drug candidates, or to achieve economies of scale. The competitive landscape includes established pharmaceutical giants and numerous smaller biotech firms, all vying for market share and investor capital.

Regulatory Implications

The proposed merger with Cullgen Inc. is subject to approval from the Nasdaq Stock Market and the China Securities Regulatory Commission (CSRC). Failure to obtain these approvals could halt the transaction. Additionally, as a biopharmaceutical company, Pulmatrix is subject to stringent FDA regulations for drug development and approval, which can impact timelines and costs.

What Investors Should Do

1. Monitor Merger Approval Status
2. Assess Cash Burn Rate and Runway
3. Evaluate Post-Merger Ownership Structure
4. Analyze the Strategic Rationale for the Merger

Key Dates

• 2025-09-30: Quarterly Period End — Represents the period for which the financial statements are reported, showing a significant decline in revenue and assets, and a substantial reduction in operating expenses.
• 2025-06-16: Pulmatrix Stockholders Approved Merger — Indicates shareholder approval for the proposed merger with Cullgen Inc., a critical step towards the transaction, though still subject to other regulatory approvals.
• 2025-04-07: Amendment No. 1 to Merger Agreement — An amendment to the merger agreement with Cullgen Inc. was filed, suggesting ongoing negotiations and adjustments to the terms of the proposed transaction.
• 2024-11-13: Agreement and Plan of Merger and Reorganization — The initial agreement for the merger between Pulmatrix and Cullgen Inc. was signed, marking the commencement of the process that is central to Pulmatrix's current strategic direction.
• 2024-12-31: End of Prior Fiscal Year — Provides a baseline for comparison of financial metrics, showing $9.521 million in cash and cash equivalents and $9.943 million in total assets, which have significantly decreased by September 30, 2025.

Glossary

iSPERSE technology

Pulmatrix's patented dry powder delivery platform designed to deliver small, dense particles efficiently to the airways. (This is the core technology Pulmatrix has focused on for developing inhaled therapeutic products.)

Merger Agreement

The contract outlining the terms and conditions for the proposed merger between Pulmatrix and Cullgen Inc. (This agreement is central to Pulmatrix's current strategic direction and future prospects, with significant financial and operational implications.)

Merger Sub

PCL Merger Sub, Inc., a wholly owned subsidiary of Pulmatrix created to facilitate the merger with Cullgen Inc. (An entity specifically formed for the merger transaction, highlighting the structure of the proposed business combination.)

Cullgen Inc.

A Delaware corporation that is the target of Pulmatrix's proposed merger. (The other party in the merger, whose success and integration are critical to Pulmatrix's future.)

CSRC

China Securities Regulatory Commission, a regulatory body whose approval is required for the merger to proceed. (An external regulatory hurdle that must be cleared for the merger to be completed, posing a potential risk.)

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any net income. (Indicates the company has historically operated at a loss, with a significant deficit of $301.390 million as of September 30, 2025.)

Year-Over-Year Comparison

Compared to the nine months ended September 30, 2024, Pulmatrix has experienced a dramatic decline in financial performance. Revenue has fallen from $7.803 million to $0, and total operating expenses have been significantly reduced from $15.614 million to $4.261 million, largely due to a sharp decrease in R&D spending from $7.160 million to $41 thousand. While the net loss has narrowed from $7.573 million to $4.234 million, this is a consequence of cost-cutting rather than revenue growth. Cash and cash equivalents have decreased by nearly 50%, highlighting a deteriorating financial position.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share PULM The Nasdaq Stock Mar
• $420,000 — red to pay Cullgen a termination fee of $420,000, and in certain other circumstances, Cu
• $2,800,000 — y Pulmatrix a termination fee of either $2,800,000 or $8,400,000. If the Merger is compl
• $8,400,000 — termination fee of either $2,800,000 or $8,400,000. If the Merger is completed, the busi

Filing Documents

• form10-q.htm (10-Q) — 813KB
• ex31-1.htm (EX-31.1) — 18KB
• ex32-1.htm (EX-32.1) — 6KB
• 0001493152-25-018256.txt ( ) — 3190KB
• pulm-20250930.xsd (EX-101.SCH) — 24KB
• pulm-20250930_cal.xml (EX-101.CAL) — 35KB
• pulm-20250930_def.xml (EX-101.DEF) — 75KB
• pulm-20250930_lab.xml (EX-101.LAB) — 198KB
• pulm-20250930_pre.xml (EX-101.PRE) — 148KB
• form10-q_htm.xml (XML) — 395KB

SIGNATURES

SIGNATURES 25 i PART I—FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements. PULMATRIX, INC. Consolidated Balance Sheets (in thousands, except share and per share data) September 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 4,794 $ 9,521 Prepaid expenses and other current assets 178 399 Total current assets 4,972 9,920 Long-term restricted cash 10 10 Other long-term assets - 13 Total assets $ 4,982 $ 9,943 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 69 $ 809 Accrued expenses and other current liabilities 180 120 Total current liabilities 249 929 Warrant liability - 67 Total liabilities 249 996 Commitments and contingencies (Note 8) - Stockholders' equity: Preferred Stock, $ 0.0001 par value — 500,000 shares authorized; 6,746 shares designated Series A convertible preferred stock; no shares issued and outstanding at September 30, 2025, and December 31, 2024 - - Common stock, $ 0.0001 par value — 200,000,000 shares authorized; 3,652,285 shares issued and outstanding at September 30, 2025, and December 31, 2024 - - Additional paid-in capital 306,123 306,103 Accumulated deficit ( 301,390 ) ( 297,156 ) Total stockholders' equity 4,733 8,947 Total liabilities and stockholders' equity $ 4,982 $ 9,943 The accompanying footnotes are an integral part of these condensed consolidated financial statements. 1 PULMATRIX, INC. Consolidated (in thousands, except share and per share data) (unaudited) 2025 2024 2025 2024 Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenues $ - $ 366 $ - $ 7,803 Operating expenses: Research and development 8 814 41 7,160 General and administrative 858 2,209 4,220 5,836 Loss on MannKind Transaction - - - 2,618 Total operating expens

View Full Filing

View this 10-Q filing on SEC EDGAR